～Strategic Acquisition to Expand its BPH Portfolio into In-office Treatment～
San Francisco, CA (UroToday.com) — Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President, and CEO: Yasuo Takeuchi) announced that it has finalized the acquisition of Israeli medical device company Medi-Tate Ltd. (“Medi-Tate” – CEO: Ido Kilemnik) following the announcement of its decision to exercise the call option in February 2021. Through this acquisition, Olympus expands its business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment and solidifies its position as a leader in the field of urological devices.